2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "OBX-115, IL2-Sparing Engineered TIL Cell Therapy for Immune Checkpoint Inhibitor-Resistant Unresectable/Metastatic Melanoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Rodabe Amaria
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Rodabe Amaria
Login to view comments.
Click here to Login